Treatment of alveolar proteinosis with «off-label» inhaled sargramostim

• Autores: Silvia Vázquez Blanco, María Encina García Mayo, Ana Belén Veiga Villaverde, Carlos Crespo Diz
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 18, Nº. 5, 2016, págs. 8-8
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Pulmonary Alveolar Proteinosis (PAP) is a rare disease characterized by the accumulation of lipoprotein material from alveolar surfactant in the alveoli of the lungs,which consequently causes a deterioration in gas exchange. It is more prevalent in young adults, who develop gradual exertional dyspnea, hypoxemia and characteristic radiological alterations. Bronchoalveolar Lavage (BAL) has proven to be the most effective treatment for PAP. The administration of inhaled Granulocyte Macrophage Colony Stimulating factor (GM-CS) would be an alternative therapy for this condition